ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research

SASKATOON - ZYUS Life Sciences Corporation (the 'Company') (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced that it has strengthened its leadership team with the appointment of Scott Livingstone to the role of Vice President of Clinical Research with its wholly owned subsidiary, ZYUS Life Sciences Inc.

In this instrumental role, Mr. Livingstone will lead the Company's clinical research initiatives and oversee ZYUS' Phase 2 Clinical Trial aimed at evaluating the efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

In addition to a wealth of experience in healthcare, Mr. Livingstone holds a Bachelor of Science in Pharmacy and a Master of Science in Clinical Pharmacy, both from the University of Saskatchewan. Scott has a proven track record of operational success in both public and private healthcare sectors, including hospital and community pharmacy practice, social sector policy and health care informatics. Prior to joining ZYUS, Mr. Livingstone served as the CEO of the Saskatchewan Health Information Network (now eHealth Saskatchewan), President and CEO of the Saskatchewan Cancer Agency, chair of both the National Steering Committee and the Saskatchewan Provincial Advisory Committee for the Pan Canadian Oncology Drug Review, and the inaugural President and CEO of the Saskatchewan Health Authority. These leadership positions have enabled Mr. Livingstone to play an active role in evidence-based assessment of oncology drugs, oncology drug safety and the sustainability of cancer control which, together with his passion for patient safety and patient-centered approach to care, makes Mr. Livingstone an ideal fit for ZYUS and its clinical research initiatives.

'We are pleased to announce Scott Livingstone's appointment to VP of Clinical Research with ZYUS Life Sciences Inc.,' said Brent Zettl, President and CEO of the Company. 'His leadership and experience will be instrumental in guiding our clinical research initiatives, particularly in overseeing the Phase 2 Clinical Trial for Trichomylin softgel capsules. This strategic addition to our team reaffirms ZYUS' commitment to the development of evidence-based solutions to address unmet patient needs.'

'I'm honored to lead ZYUS' clinical research initiatives, driven by a profound dedication to improving lives through innovative discoveries,' said Mr. Livingstone. 'With a dedicated team and a relentless pursuit of scientific innovation, we aim to uncover transformative cannabinoid-based therapies that benefit patients globally.'

About the Phase 2 Clinical Trial

Following the Company's announcement on December 5, 2023, ZYUS is moving forward with the decision to fast-track and progress directly to a full Phase 2 Clinical Trial in Canada. This trial aims to evaluate the preliminary efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

About ZYUS Life Sciences Corporation

ZYUS is a publicly traded Canadian-based life sciences company focused on the global development and commercialization of regulated cannabinoid-based pharmaceutical drug product candidates. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP/EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The ZYUS vision is to reimagine the potential of pain therapeutics by pursuing regulatory approval of cannabinoid formulations and elevating cannabinoids as a standard of care in pursuit of transformational impact on patients' lives. ZYUS: Advancing the Science of Well-Being.

Cautionary Note Regarding Forward-Looking Statements

This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin softgel capsules, introduce products that act as alternatives to current pain management therapies, advance Phase 2 clinical development of Trichomylin softgel capsules and build shareholder value. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin softgel capsules, introduce products that act as alternatives to current pain management therapies, advance Phase 2 clinical development of Trichomylin softgels, and build shareholder value are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies or advance Phase 2 clinical development of Trichomylin softgels. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.

Contact:

Email: [e-mail]

Tel: [phone]

(C) 2024 Electronic News Publishing, source ENP Newswire